Josh Reisberg outlines the foundation of a broad, overall defense strategy for generic companies embroiled in Hatch-Waxman patent infringement litigations.
Josh Reisberg
Advertisement
Josh Reisberg is counsel at Axinn Veltrop & Harkrider LLP (New York, NY).
Articles by Josh Reisberg
Advertisement
Latest Updated Articles
Beyond the Merits: Generic Company Defense StrategiesJune 22nd 2018
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly Enters $7.8 Billion Agreement to Acquire Centessa Pharmaceuticals to Advance Sleep-Wake Treatments
2
Novo Nordisk Launches Multi-Month Subscription Program for Wegovy
3
Merck Enters $838 Million Research & Development Collaboration with Infinimmune
4
How Will MFN’s Effects on Medicare Impact Innovation?
5